|1.||Federici, A B: 5 articles (05/2012 - 03/2000)|
|2.||Franchini, Massimo: 5 articles (01/2010 - 11/2003)|
|3.||Federici, Augusto B: 4 articles (05/2008 - 03/2003)|
|4.||Tagliaferri, Annarita: 3 articles (01/2010 - 11/2003)|
|5.||Auerswald, Günter: 3 articles (05/2008 - 04/2002)|
|6.||Budde, Ulrich: 3 articles (01/2007 - 04/2002)|
|7.||Ernstgård, Lena: 2 articles (12/2015 - 07/2012)|
|8.||Johanson, Gunnar: 2 articles (12/2015 - 07/2012)|
|9.||Sjögren, Bengt: 2 articles (12/2015 - 07/2012)|
|10.||Kreuz, W: 2 articles (05/2014 - 11/2008)|
01/15/2002 - "A multicenter, prospective study has been conducted in 81 patients with VWD (15 patients with type 1, 34 with type 2, and 32 with type 3 disease) to investigate the efficacy of a high-purity factor VIII/von Willebrand factor (FVIII/VWF) concentrate for treatment of bleeding and surgical prophylaxis. "
09/01/2001 - "Early transfusion of factor VIII/von Willebrand factor concentrates seems to be effective in the treatment of gastrointestinal bleeding in patients with von Willebrand type III disease."
06/01/2010 - "In one of them, delayed bleeding occurred 15 days later requiring treatment with Factor VIII/von Willebrand factor concentrate. "
05/01/2008 - "Haemate P is a human, plasma-derived VWF/FVIII medicinal product, which was first licensed in Germany in 1981 for the treatment of HA-associated bleeding. "
07/01/2007 - "Fifty-nine patients were treated with Haemate P because of 280 spontaneous bleeding episodes. "
|2.||von Willebrand Diseases (von Willebrand's Disease)
11/01/2002 - "Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study."
05/01/2012 - " (Fanhdi and Alphanate Italian Retrospective Study in Willebrand disease) study, 120 von Willebrand disease (VWD) patients treated with Fanhdi(®) or Alphanate(®) were retrospectively analysed. "
07/01/2010 - "Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study."
12/01/2007 - "Recently, three multicentre prospective international studies have been carried out to evaluate the clinical efficacy and safety of Fanhdi [high-purity, double-inactivated plasma-derived factor VIII/von Willebrand factor (VWF) concentrate] in patients with von Willebrand's disease (VWD). "
04/01/2005 - "Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys."
|3.||Hemophilia A (Haemophilia)
11/01/2014 - "The availability of pasteurized, and therefore virus-safe, plasma-derived, clotting factor concentrates, such as Haemate P(®) and Beriate(®) P in Germany and other countries, dramatically improved the quality of life and life expectancy of haemophilia patients. "
04/01/2005 - "The advent of virally inactivated factor VIII/von Willebrand factor (FVIII/VWF) concentrates, originally developed for the treatment of patients with hemophilia, provided improved therapy for VWD. "
01/01/2013 - "The Grifols-Immune Tolerance Induction (G-ITI) Study represents the largest group of haemophilia A inhibitor patients treated with a single pdFVIII/VWF concentrate (Alphanate(®)/Fanhdi(®)) to be reported to date. "
05/01/2014 - "A review of immune tolerance induction with Haemate P in haemophilia A."
01/01/2010 - "Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor."
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
05/01/2004 - "Fibrinogen, thrombocytes, factor VII, factor VIII, von Willebrand factor (vWF), thrombomodulin (TM), plasminogen activator inhibitor--type 1 (PAI-1), tissue-plasminogen activator (t-PA) and other haemostatic factors, were described as more or less helpful in estimation of risk of occurrence of coronary artery disease and its cardiovascular complications. "
11/01/1984 - "Thus, Factor VIII/von Willebrand factor (VIII/VWF) may mediate not only the adhesion of platelets to subendothelium but also platelet-platelet attachments necessary for normal thrombus development. "
11/01/2008 - "Haemate P/Humate-P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades of clinical use. "
07/31/1987 - "Platelet-membrane receptor inhibition to the fibrinogen receptor, factor VIII-von Willebrand factor or both may be necessary acutely to sufficiently reduce acute platelet-thrombus deposition."
07/01/1987 - "To determine if factor VIII-von Willebrand factor (vWF) complex is involved in the thrombosis associated with asparaginase-prednisone-vincristine induction therapy for acute lymphoblastic leukemia, plasma vWF was analyzed by sodium dodecyl sulfate-agarose gel electrophoresis and crossed immunoelectrophoresis. "
|1.||von Willebrand factor drug combination factor VIII
|2.||von Willebrand Factor
|3.||human F8 protein
|4.||Deamino Arginine Vasopressin (Desmopressin)
|5.||Fibrinogen (Factor I)
|6.||Factor VII (Proconvertin)
|7.||Plasminogen Activators (Plasminogen Activator)
|8.||Tissue Plasminogen Activator (Alteplase)
|10.||Factor VIII (Coagulation Factor VIII)
|1.||Minor Surgical Procedures (Minor Surgery)
|3.||Lithotripsy (Extracorporeal Shockwave Lithotripsy)